Not long after the initial findings of the positive effects of angiotensin-converting enzyme (ACE) inhibition on prognosis for patients with congestive heart failure (CHF), a controversy commenced as to whether there is a negative interaction between ACE inhibition and aspirin.1
Since one of the most important underlying causes of CHF is coronary artery disease, this question is of utmost clinical importance. The fact that this topic is still relevant > 10 years after the initiation of the controversy indicates the difficulty inherent in resolving the question. In this issue of CHEST (see page 1250), Aumégeat et al present their data showing no negative interaction in their CHF cohort. Does this mean that the controversy is finally resolved?